Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells

Cancer Letters

Volumn 301, Issue 1, 2011, Pages 17-28

  Wedel, Steffen ^a   Hudak, Lukasz ^a   Seibel, Jens Michael ^a   Juengel, Eva ^a   Tsaur, Igor ^a   Haferkamp, Axel ^a   Blaheta, Roman A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

MTor inhibitor; Prostate carcinoma; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CELL CYCLE PROTEIN; EVEROLIMUS; INTEGRIN;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL CYCLE ARREST; CELL SPECIFICITY; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UMBILICAL VEIN;

CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PURINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 78650551103     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.11.003     Document Type: Article

References (54)

1. Zellweger T., Ninck C., Bloch M., Mirlacher M., Koivisto P.A., Helin H.J., Mihatsch M.J., Gasser T.C., Bubendorf L. Expression patterns of potential therapeutic targets in prostate cancer. Int. J. Cancer 2005, 113:619-628.
2. Mimeault M., Venkatraman G., Johansson S.L., Moore E., Henichart J.P., Depreux P., Lin M.F., Batra S.K. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int. J. Cancer 2007, 120:160-169.
3. Bratland A., Boender P.J., Høifødt H.K., Østensen I.H., Ruijtenbeek R., Wang M.Y., Berg J.P., Lilleby W., Fodstad Ø., Ree A.H. Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling. Clin. Exp. Metastasis 2009, 26:485-496.
4. Pezaro C., Rosenthal M.A., Gurney H., Davis I.D., Underhill C., Boyer M.J., Kotasek D., Solomon B., Toner G.C. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am. J. Clin. Oncol. 2009, 32:338-341.
5. Small E.J., Fontana J., Tannir N., DiPaola R.S., Wilding G., Rubin M., Iacona R.B., Kabbinavar F.F. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007, 100:765-769.
6. Gross M., Higano C., Pantuck A., Castellanos O., Green E., Nguyen K., Agus D.B. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007, 7:142.
7. Li R., Younes M., Wheeler T.M., Scardino P., Ohori M., Frolov A., Ayala G. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004, 58:193-199.
8. Sonpavde G., Periman P.O., Bernold D., Weckstein D., Fleming M.T., Galsky M.D., Berry W.R., Zhan F., Boehm K.A., Asmar L., Hutson T.E. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. 2009, 21:319-324.
9. Dror Michaelson M., Regan M.M., Oh W.K., Kaufman D.S., Olivier K., Michaelson S.Z., Spicer B., Gurski C., Kantoff P.W., Smith M.R. Phase II study of sunitinib in men with advanced prostate cancer. Ann. Oncol. 2009, 20:913-920.
10. Aragon-Ching J.B., Jain L., Gulley J.L., Arlen P.M., Wright J.J., Steinberg S.M., Draper D., Venitz J., Jones E., Chen C.C., Figg W.D., Dahut W.L. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 2009, 103:1636-1640.
11. Viloria-Petit A., Crombet T., Jothy S., Hicklin D., Bohlen P., Schlaeppi J.M., Rak J., Kerbel R.S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001, 61:5090-5101.
12. Kedar D., Baker C.H., Killion J.J., Dinney C.P., Fidler I.J. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 2002, 8:3592-3600.
13. Traxler P., Allegrini P.R., Brandt R., Brueggen J., Cozens R., Fabbro D., Grosios K., Lane H.A., McSheehy P., Mestan J., Meyer T., Tang C., Wartmann M., Wood J., Caravatti G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004, 64:4931-4941.
14. Naumov G.N., Nilsson M.B., Cascone T., Briggs A., Straume O., Akslen L.A., Lifshits E., Byers L.A., Xu L., Wu H.K., Jänne P., Kobayashi S., Halmos B., Tenen D., Tang X.M., Engelman J., Yeap B., Folkman J., Johnson B.E., Heymach J.V. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 2009, 15:3484-3494.
15. Horti J., Widmark A., Stenzl A., Federico M.H., Abratt R.P., Sanders N., Pover G.M., Bodrogi I. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother. Radiopharm. 2009, 24:175-180.
16. Natale R.B., Bodkin D., Govindan R., Sleckman B.G., Rizvi N.A., Capó A., Germonpré P., Eberhardt W.E., Stockman P.K., Kennedy S.J., Ranson M. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J. Clin. Oncol. 2009, 27:2523-2529.
17. DeHaan A.M., Wolters N.M., Keller E.T., Ignatoski K.M. EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate 2009, 69:528-537.
18. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 2008, 11:32-50.
19. Wu Z., Gioeli D., Conaway M., Weber M.J., Theodorescu D. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 2008, 68:935-944.
20. Festuccia C., Gravina G.L., Muzi P., Millimaggi D., Dolo V., Vicentini C., Bologna M. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate 2008, 68:965-974.
21. Vivar O.I., Lin C.L., Firestone G.L., Bjeldanes L.F. 3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochem. Pharmacol. 2009, 78:469-476.
22. Neuwirt H., Puhr M., Santer F.R., Susani M., Doppler W., Marcias G., Rauch V., Brugger M., Hobisch A., Kenner L., Culig Z. Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am. J. Pathol. 2009, 174:1921-1930.
23. Liu P., Kao T.P., Huang H. CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene 2008, 27:4733-4744.
24. Chen S., Xu Y., Yuan X., Bubley G.J., Balk S.P. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc. Natl. Acad. Sci. USA 2006, 103:15969-15974.
25. Gorshtein A., Rubinfeld H., Kendler E., Theodoropoulou M., Cerovac V., Stalla G.K., Cohen Z.R., Hadani M., Shimon I. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr. Relat. Cancer 2009, 16:1017-1027.
26. Shi Y., Sharma A., Wu H., Lichtenstein A., Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J. Biol. Chem. 2005, 280:10964-10973.
27. Chen X., Thakkar H., Tyan F., Gim S., Robinson H., Lee C., Pandey S.K., Nwokorie C., Onwudiwe N., Srivastava R.K. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001, 20:6073-6083.
28. Kostenuik P.J., Sanchez-Sweatman O., Orr F.W., Singh G. Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin. Exp. Metastasis 1996, 14:19-26.
29. Lesniak D., Xu Y., Deschenes J., Lai R., Thoms J., Murray D., Gosh S., Mackey J.R., Sabri S., Abdulkarim B. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res. 2009, 69:8620-8628.
30. Puigvert J.C., Huveneers S., Fredriksson L., op het Veld M., van de Water B., Danen E.H. Cross-talk between integrins and oncogenes modulates chemosensitivity. Mol. Pharmacol. 2009, 75:947-955.
31. Folgiero V., Avetrani P., Bon G., Di Carlo S.E., Fabi A., Nisticò C., Vici P., Melucci E., Buglioni S., Perracchio L., Sperduti I., Rosanò L., Sacchi A., Mottolese M., Falcioni R. Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. PLoS One 2008, 3:e1592.
32. de Amicis F., Lanzino M., Kisslinger A., Calì G., Chieffi P., Andò S., Mancini F.P., Tramontano D. Loss of proline-rich tyrosine kinase 2 function induces spreading and motility of epithelial prostate cells. J. Cell Physiol. 2006, 209:74-80.
33. Romanov V.I., Goligorsky M.S. RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro. Prostate 1999, 39:108-118.
34. Mirtti T., Nylund C., Lehtonen J., Hiekkanen H., Nissinen L., Kallajoki M., Alanen K., Gullberg D., Heino J. Regulation of prostate cell collagen receptors by malignant transformation. Int. J. Cancer 2006, 118:889-898.
35. Liu Y., Pixley R., Fusaro M., Godoy G., Kim E., Bromberg M.E., Colman R.W. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Oncogene 2009, 28:2756-2765.
36. Kwon G.T., Cho H.J., Chung W.Y., Park K.K., Moon A., Park J.H. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. J. Nutr. Biochem. 2009, 20:663-676.
37. Lai T.H., Fong Y.C., Fu W.M., Yang R.S., Tang C.H. Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins. Prostate 2008, 68:1341-1353.
38. Bisanz K., Yu J., Edlund M., Spohn B., Hung M.C., Chung L.W., Hsieh C.L. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol. Ther. 2005, 12:634-643.
39. Hao J., Jackson L., Calaluce R., McDaniel K., Dalkin B.L., Nagle R.B. Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer. Am. J. Pathol. 2001, 158:1129-1135.
40. Oertl A., Relja B., Makarevic J., Weich E., Höfler S., Jones J., Jonas D., Bratzke H., Baer P.C., Blaheta R.A. Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid. Int. J. Mol. Med. 2006, 18:347-354.
41. Kiefer J.A., Farach-Carson M.C. Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: implications for enhanced growth in the bone microenvironment. Matrix Biol. 2001, 20:429-437.
42. Sun Y.X., Fang M., Wang J., Cooper C.R., Pienta K.J., Taichman R.S. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007, 67:61-73.
43. Pontes-Junior J., Reis S.T., Dall'oglio M., Neves de Oliveira L.C., Cury J., Carvalho P.A., Ribeiro-Filho L.A., Moreira Leite K.R., Srougi M. Evaluation of the expression of integrins and cell adhesion molecules through tissue microarray in lymph node metastases of prostate cancer. J. Carcinog. 2009, 8:3.
44. Davis T.L., Cress A.E., Dalkin B.L., Nagle R.B. Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma. Prostate 2001, 46:240-248.
45. Nagakawa O., Akashi T., Hayakawa Y., Junicho A., Koizumi K., Fujiuchi Y., Furuya Y., Matsuda T., Fuse H., Saiki I. Differential expression of integrin subunits in DU-145/AR prostate cancer cells. Oncol. Rep. 2004, 12:837-841.
46. Moretti R.M., Marelli M.M., Motta M., Limonta P. Role of the orphan nuclear receptor ROR alpha in the control of the metastatic behavior of androgen-independent prostate cancer cells. Oncol. Rep. 2002, 9:1139-1143.
47. Gaietta G., Redelmeier T.E., Jackson M.R., Tamura R.N., Quaranta V. Quantitative measurement of alpha 6 beta 1 and alpha 6 beta 4 integrin internalization under cross-linking conditions: a possible role for alpha 6 cytoplasmic domains. J. Cell Sci. 1994, 107:3339-3349.
48. Graff J.R., Deddens J.A., Konicek B.W., Colligan B.M., Hurst B.M., Carter H.W., Carter J.H. Integrin-linked kinase expression increases with prostate tumor grade. Clin. Cancer Res. 2001, 7:1987-1991.
49. Liu L., Chen L., Chung J., Huang S. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 2008, 27:4998-5010.
50. Walden P.D., Globina Y., Nieder A. Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase. Urol. Res. 2004, 32:261-265.
51. Stagge V., Seufferlein T., Dürschmied D., Menke A., Adler G., Beil M. Integrin-mediated differentiation of a pancreatic carcinoma cell line is independent of FAK or MAPK activation levels. Pancreas 2001, 23:236-245.
52. Yang Z., Lei Z., Li B., Zhou Y., Zhang G.M., Feng Z.H., Zhang B., Shen G.X., Huang B. Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling. Cancer Sci. 2010, 101:494-500.
53. Marelli M.M., Moretti R.M., Procacci P., Motta M., Limonta P. Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling. Int. J. Oncol. 2006, 28:723-730.
54. Skogseth H., Holt R.U., Larsson E., Halgunset J. Tyrosine kinase inhibitors alter adhesivity of prostatic cancer cells to extracellular matrix components. APMIS 2006, 114:225-233.